Ignyta (Ignyta) Retained Earnings : $-348.70 Mil (As of Sep. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Ignyta Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Ignyta's retained earnings for the quarter that ended in Sep. 2017 was $-348.70 Mil.

Ignyta's quarterly retained earnings declined from Mar. 2017 ($-291.82 Mil) to Jun. 2017 ($-320.10 Mil) and declined from Jun. 2017 ($-320.10 Mil) to Sep. 2017 ($-348.70 Mil).

Ignyta's annual retained earnings declined from Dec. 2014 ($-55.56 Mil) to Dec. 2015 ($-148.02 Mil) and declined from Dec. 2015 ($-148.02 Mil) to Dec. 2016 ($-251.66 Mil).

Ignyta Retained Earnings Historical Data

The historical data trend for Ignyta's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ignyta Retained Earnings Chart

Ignyta Annual Data

Trend

Aug12

Aug13

Dec14

Dec15

Dec16

Retained Earnings

-0.02

-55.56

-148.02

-251.66

Ignyta Quarterly Data
	Nov12	Feb13	May13	Aug13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Retained Earnings	Get a 7-Day Free Trial															-223.45	-251.66	-291.82	-320.10	-348.70

Ignyta Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Ignyta (NAS:RXDX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Ignyta (Ignyta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ignyta.com

Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.

Executives

James L Freddo	director	3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani	officer: Chief Medical Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim	director, 10 percent owner, officer: President, CEO & Director	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko	officer: Chief Financial Officer	C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky	officer: GM, Immuno-Oncology/SVP Sp Ops	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis	officer: General Counsel and Secretary	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin • 03-23-2021